Predicting the Probability of Experiencing Clinically Significant Drug–Drug Interactions Involving Boceprevir-Containing Hepatitis C Therapy Among Patients Coinfected with Hepatitis C and HIV

Patel, Nimish; Veve, Michael P; Nasiri, Mohammad Reza; Bliss, Steven; McNutt, Louise‐Anne; Lazariu, Victoria; Miller, Christopher D.

doi:10.1089/apc.2014.0149

Cited by 1 publication

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study, one of the largest population-based drug–drug interaction studies, focused on patients with HCV monoinfection. The results presented here are consistent with other publications [ 4 , 9 , 10 , 15 ]. It was observed that polypharmacy was an issue among patients with HCV monoinfection and these patients are vulnerable to the effects of XDDI.…”

Section: Discussionsupporting

confidence: 94%

“…The majority of other population-based drug–drug interaction studies have been focused on patients with HIV/HCV coinfection [ 9 , 10 ]. The present study, one of the largest population-based drug–drug interaction studies, focused on patients with HCV monoinfection.…”

Section: Discussionmentioning

confidence: 99%

“…However, there is little data quantifying the excess frequency of XDDIs that occur between SIM- or SOF-containing treatment regimens when added to the existing medication profiles of HCV monoinfected patients. The majority of this work has been focused on patients with human immunodeficiency virus (HIV)/HCV coinfection [ 9 , 10 ]. An understanding of the frequency and predictors of XDDIs when either SIM- or SOF-containing therapy is considered for initiation will aid clinicians in managing the most appropriate therapy for a given patient with HCV monoinfection.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A Cross-Sectional Study Comparing the Frequency of Drug Interactions After Adding Simeprevir- or Sofosbuvir-Containing Therapy to Medication Profiles of Hepatitis C Monoinfected Patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

IntroductionThis study compares the expected occurrence of contraindicated drug–drug interactions (XDDIs) when simeprevir (SIM)- or sofosbuvir (SOF)-containing therapy is added to medication profiles of patients with hepatitis C (HCV) monoinfection to quantify, in relative terms, the population-based risk of XDDIs. Second, this study identified the predictors of XDDIs when HCV therapies are added to medication profiles.MethodsA cross-sectional study was performed among Veterans’ Affairs patients. Inclusion criteria were: (1) age ≥18 years, (2) HCV infection, and (3) availability of a medication list. Patients with human immunodeficiency virus were excluded. Demographics, comorbidities, year of HCV diagnosis, and most recent medication list were collected from medical records. The primary outcome was the presence of XDDIs involving HCV therapy and the medications in the patient’s home medication list after the addition of either SIM- or SOF-containing regimens. To define XDDIs, Lexi-Interact drug interaction software was used.Results4,251 patients were included. The prevalence of XDDIs involving SIM- or SOF-containing therapy were 12.6% and 4.7% (p < 0.001), respectively. In multivariable analyses examining the predictors of XDDIs involving SIM-containing therapy, the only medication-related predictor was use of ≥6 home medications (odds ratio OR 4.58, 95% confidence interval CI 3.54–5.20, p < 0.001). Similarly, use of ≥6 home medications was also the only variable associated with an increased probability of XDDI involving SOF-containing therapy (OR 3.83, 95% CI 2.57–5.70, p < 0.001).ConclusionsSofosbuvir-containing therapy had a lower frequency of XDDIs than SIM-containing therapy. Polypharmacy with various classes of home medications predicted XDDIs involving SIM- or SOF-containing therapy.Electronic supplementary materialThe online version of this article (doi:10.1007/s40121-015-0058-x) contains supplementary material, which is available to authorized users.

show abstract